Literature DB >> 4703766

A murine renal cell carcinoma.

G P Murphy, W J Hrushesky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4703766     DOI： 10.1093/jnci/50.4.1013

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  31 in total

1.  Cross-talk between tumors can affect responses to therapy.

Authors:  Christel Devaud; Liza B John; Jennifer A Westwood; Carmen Sm Yong; Paul A Beavis; Reto A Schwendener; Phillip K Darcy; Michael H Kershaw
Journal:  Oncoimmunology       Date:  2015-06-17       Impact factor: 8.110

2.  Development and characterization of a new murine renal tumor model. Chemotherapeutic results.

Authors:  M Vandendris; P Dumont; R Heimann; G Atassi
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

3.  Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources.

Authors:  S K Gregorian; J R Battisto
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.

Authors:  Christel Devaud; Jennifer A Westwood; Liza B John; Jacqueline K Flynn; Sophie Paquet-Fifield; Connie P M Duong; Carmen S M Yong; Hollie J Pegram; Steven A Stacker; Marc G Achen; Trina J Stewart; Linda A Snyder; Michele W L Teng; Mark J Smyth; Phillip K Darcy; Michael H Kershaw
Journal:  Mol Ther       Date:  2013-09-19       Impact factor: 11.454

5.  Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.

Authors:  Jennifer A Westwood; Phillip K Darcy; Preethi Mayura Guru; Janelle Sharkey; Hollie J Pegram; Sally M Amos; Mark J Smyth; Michael H Kershaw
Journal:  J Transl Med       Date:  2010-04-28       Impact factor: 5.531

6.  Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-alpha and interleukin-2.

Authors:  K Sonouchi; T A Hamilton; C S Tannenbaum; R R Tubbs; R Bukowski; J H Finke
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

7.  Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy.

Authors:  Manikkam Suthanthiran; Minoru Hojo; Mary Maluccio; Daniel J Boffa; Fu L Luan
Journal:  Trans Am Clin Climatol Assoc       Date:  2009

8.  Therapeutic effects of a synthetic peptide of C-reactive protein in pre-clinical tumor models.

Authors:  B P Barna; D A Eppstein; M J Thomassen; J J Nestor; T Ho; S V Medendorp; S D Deodhar
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

9.  Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo.

Authors:  Maryam Ahmadi; David C Emery; David J Morgan
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

10.  In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31362.

Authors:  T Utsugi; C P Dinney; J J Killion; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.